Overview

• The injection, ocrelizumab, can be administered in 10 minutes compared to the current four-hour infusion process.
• It is expected to benefit around 9,000 MS patients in England, Wales, and Northern Ireland.
• The new method has been approved by the Medicines and Healthcare products Regulatory Agency and will be available within weeks.
• Ocrelizumab targets B cells to reduce the immune response that damages nerve coverings in MS patients.
• The change is anticipated to free up hospital resources and allow more time for clinicians to treat additional patients.